Home › Therapeutic areas › Oncology › Solid Tumors
Solid Tumors (25 companies)
Companies with an active program in Solid Tumors.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ADAG | Adagene | Oncology | 4 | Phase 2 | $99.4M | 10 |
| ANTX | AN2 Therapeutics | HematologyInfectious Disease+1 Rare | 1 | Phase 2 | $161M | 6 |
| APVO | Aptevo Therapeutics | Oncology | 2 | Phase 1 | $1.6M | 8 |
| AVBP | ArriVent BioPharma | Oncology | 3 | Phase 3 | $553M | 7 |
| ARVN | Arvinas | NeurologyOncology Rare | 2 | Approved | $447M | 10 |
| COGT | Cogent Biosciences | HematologyOncology Rare | 2 | NDA Submitted | $4.85B | 7 |
| CHRS | Coherus Oncology | Oncology | 1 | Approved | $74.0M | 5 |
| CGEN | Compugen | Oncology | 1 | Phase 3 | $191M | 7 |
| CBIO | Crescent Biopharma | Oncology | 1 | Phase 2 | $507M | 10 |
| ERAS | Erasca | Oncology | 2 | Phase 1 | $4.87B | 5 |
| EXEL | Exelixis | CardiovascularOncology | 3 | Approved | $16.7B | 23 |
| FATE | Fate Therapeutics | ImmunologyOncology+1 Rare | 2 | Phase 2 | $124M | 10 |
| IMRX | Immuneering | Oncology | 1 | Phase 3 | $224M | 5 |
| IMNM | Immunome | Oncology Rare | 4 | NDA Submitted | $2.03B | 9 |
| MDNAF | Medicenna Therapeutics | Oncology | 1 | Phase 2 | $14.8M | 10 |
| INKT | MiNK Therapeutics | ImmunologyOncology+1 Rare | 1 | Phase 2 | $47.7M | 8 |
| NBP | NovaBridge Biosciences | OncologyOphthalmology | 1 | Phase 2 | $95.4M | 7 |
| NVCT | Nuvectis Pharma | HematologyOncology+1 Rare | 1 | Phase 3 | $660M | 9 |
| KTTA | Pasithea Therapeutics | NeurologyOncology Rare | 1 | Phase 1 | $16.0M | 4 |
| CATX | Perspective Therapeutics | Oncology | 1 | Phase 1 | $104M | 5 |
| PMVP | PMV Pharmaceuticals | Oncology | 1 | Phase 2 | $92.2M | 7 |
| RXRX | Recursion Pharmaceuticals | Oncology | 3 | Phase 2 | $1.69B | 6 |
| STRO | Sutro Biopharma | Oncology | 3 | Phase 1 | $148M | 3 |
| VIR | Vir Biotechnology | Infectious DiseaseOncology Rare | 1 | Phase 3 | $1.58B | 6 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.59B | 28 |
No companies match.